Bean extract may tame blood sugar spikes after carbs
NCT ID NCT07466667
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This study tests whether a supplement called Phaseolean, made from white kidney beans, can help healthy adults keep their blood sugar steady after eating carb-rich foods like white bread. Twelve participants will take different doses of the supplement or a control before a meal, and their blood sugar and feelings of fullness will be measured. It's an early, small study in healthy people, so any benefits are uncertain and not yet proven for those with diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Phaseolean (White Kidney Bean Extract)
- What this could lead to
- If it works, this could point toward a natural supplement to help manage blood sugar spikes after meals.
- What could go wrong
- This is a very small, early trial in healthy people only. Results may not apply to those with diabetes or other conditions, and the supplement may have no real effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NovoBliss Research
Ahmedabad, Gujarat, 382481, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test